[{"id":"f717121f-6913-41a9-bfde-2932abad4e9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06891742","created_at":"2025-06-28T16:10:54.772Z","updated_at":"2025-06-28T16:10:54.772Z","phase":"Phase 1","brief_title":"Phase I Study of OriC902 in Treatment of Advanced HCC","source_id_and_acronym":"NCT06891742","lead_sponsor":"Peking University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/24/2025","start_date":" 02/24/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2025-03-24"},{"id":"8928481a-724a-435c-8656-726fa0e4aab3","acronym":"GLYCAR","url":"https://clinicaltrials.gov/study/NCT02905188","created_at":"2021-03-12T22:55:55.778Z","updated_at":"2025-02-25T12:26:31.981Z","phase":"Phase 1","brief_title":"Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)","source_id_and_acronym":"NCT02905188 - GLYCAR","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • GLYCAR T cells • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 03/28/2019","start_date":" 03/28/2019","primary_txt":" Primary completion: 11/17/2021","primary_completion_date":" 11/17/2021","study_txt":" Completion: 01/06/2023","study_completion_date":" 01/06/2023","last_update_posted":"2025-02-24"},{"id":"d659973c-81cd-4913-bbf3-c30346459d0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06641453","created_at":"2025-02-25T20:22:20.737Z","updated_at":"2025-02-25T20:22:20.737Z","phase":"Phase 1/2","brief_title":"CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma","source_id_and_acronym":"NCT06641453","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/15/2024","start_date":" 11/15/2024","primary_txt":" Primary completion: 11/15/2027","primary_completion_date":" 11/15/2027","study_txt":" Completion: 11/15/2028","study_completion_date":" 11/15/2028","last_update_posted":"2024-10-16"},{"id":"6e64d8bc-6c09-4f91-9b5f-8fae5114fc10","acronym":"","url":"https://clinicaltrials.gov/study/NCT05003895","created_at":"2021-08-13T13:53:05.789Z","updated_at":"2024-07-02T16:34:38.043Z","phase":"Phase 1","brief_title":"GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC)","source_id_and_acronym":"NCT05003895","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 12/08/2021","start_date":" 12/08/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-05"},{"id":"fc576648-b27b-43b1-9571-31217d6f4b7e","acronym":"ATHENA","url":"https://clinicaltrials.gov/study/NCT06084884","created_at":"2023-10-16T15:12:58.306Z","updated_at":"2024-07-02T16:35:02.183Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma","source_id_and_acronym":"NCT06084884 - ATHENA","lead_sponsor":"AstraZeneca","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 11/27/2023","start_date":" 11/27/2023","primary_txt":" Primary completion: 12/13/2027","primary_completion_date":" 12/13/2027","study_txt":" Completion: 12/13/2027","study_completion_date":" 12/13/2027","last_update_posted":"2024-05-21"},{"id":"a50db79e-f985-4b65-9c1b-fc575cc8904a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04715191","created_at":"2021-01-21T06:52:06.961Z","updated_at":"2024-07-02T16:35:05.923Z","phase":"Phase 1","brief_title":"Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors","source_id_and_acronym":"NCT04715191","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • GLYCAR T cells • GPC3-CAR and IL15 plus IL21 • cyclophosphamide intravenous"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/03/2024","start_date":" 07/03/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 07/03/2041","study_completion_date":" 07/03/2041","last_update_posted":"2024-05-06"},{"id":"88f5020d-8814-488d-b3cb-c97d3b33e81f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05155189","created_at":"2021-12-13T14:12:43.066Z","updated_at":"2024-07-02T16:35:11.399Z","phase":"Phase 1","brief_title":"A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma","source_id_and_acronym":"NCT05155189","lead_sponsor":"Zhejiang University","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • AZD7003"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 12/09/2021","start_date":" 12/09/2021","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2041","study_completion_date":" 05/01/2041","last_update_posted":"2024-04-04"},{"id":"f07104db-d6a9-438c-a618-ef3832fea178","acronym":"","url":"https://clinicaltrials.gov/study/NCT05652920","created_at":"2022-12-15T14:58:23.337Z","updated_at":"2024-07-02T16:35:11.688Z","phase":"Phase 1/2","brief_title":"Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC","source_id_and_acronym":"NCT05652920","lead_sponsor":"OriCell Therapeutics Co., Ltd.","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ori-C101"],"overall_status":"Recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-04-03"},{"id":"6db954e8-43a6-4f85-805a-10d3f605b83c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05783570","created_at":"2023-03-24T16:04:17.343Z","updated_at":"2024-07-02T16:35:14.560Z","phase":"Phase 1","brief_title":"To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307","source_id_and_acronym":"NCT05783570","lead_sponsor":"Eutilex","biomarkers":" IFNG • IL6 • TNFA • GPC3 • IL2 • IL10 • IL18","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • GPC3 • IL2 • IL10 • IL18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EU307"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 08/24/2023","start_date":" 08/24/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-15"},{"id":"159f03cc-8156-48bf-876e-731616d2716a","acronym":"DUET-1","url":"https://clinicaltrials.gov/study/NCT05120271","created_at":"2021-11-15T12:53:36.567Z","updated_at":"2024-07-02T16:35:23.821Z","phase":"Phase 1/2","brief_title":"BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors","source_id_and_acronym":"NCT05120271 - DUET-1","lead_sponsor":"Sotio Biotech Inc.","biomarkers":" EGFR • ALK • BRCA • GPC3","pipe":" | ","alterations":" EGFR mutation • ALK translocation • BRCA mutation • GPC3 expression • GPC3 overexpression","tags":["EGFR • ALK • BRCA • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation • BRCA mutation • GPC3 expression • GPC3 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BOXR1030"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 05/18/2022","start_date":" 05/18/2022","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 12/01/2041","study_completion_date":" 12/01/2041","last_update_posted":"2024-01-11"},{"id":"50719c7c-1135-486c-b135-71ad28c7d4ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT04405778","created_at":"2021-01-19T19:50:10.388Z","updated_at":"2024-07-02T16:35:25.199Z","phase":"Phase 1","brief_title":"A Study of TAK-102 in Adult With Previously-Treated Solid Tumors","source_id_and_acronym":"NCT04405778","lead_sponsor":"Takeda","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NIB102"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 07/10/2020","start_date":" 07/10/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-12-27"},{"id":"a01a09c6-25d1-401d-bdb6-9d279e055486","acronym":"","url":"https://clinicaltrials.gov/study/NCT05070156","created_at":"2021-10-07T12:53:00.198Z","updated_at":"2024-07-02T16:35:26.134Z","phase":"Phase 1","brief_title":"B010-A Injection for Treating Patients With GPC3 Positive Advanced Hepatocellular Carcinoma","source_id_and_acronym":"NCT05070156","lead_sponsor":"Tongji University","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e B010-A"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3","initiation":"Initiation: 10/29/2021","start_date":" 10/29/2021","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2023-12-15"},{"id":"99889667-7df9-4ba0-9746-9b7586ccaa67","acronym":"","url":"https://clinicaltrials.gov/study/NCT05779917","created_at":"2023-03-22T14:03:05.395Z","updated_at":"2024-07-02T16:35:29.095Z","phase":"Phase 1","brief_title":"Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers","source_id_and_acronym":"NCT05779917","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mesothelin/GPC3/GUCY2C-CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/10/2023","start_date":" 03/10/2023","primary_txt":" Primary completion: 03/10/2026","primary_completion_date":" 03/10/2026","study_txt":" Completion: 03/10/2033","study_completion_date":" 03/10/2033","last_update_posted":"2023-11-15"},{"id":"ee94b79f-8da0-407f-bc94-ca8110bf7bd6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05103631","created_at":"2021-11-02T17:57:08.812Z","updated_at":"2024-07-02T16:35:39.256Z","phase":"Phase 1","brief_title":"Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors","source_id_and_acronym":"NCT05103631","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AGAR T cells • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 06/17/2021","start_date":" 06/17/2021","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 12/01/2039","study_completion_date":" 12/01/2039","last_update_posted":"2023-08-23"},{"id":"495b5eb1-f870-47b8-a171-3b0065ad59ef","acronym":"CT0180-CG1203","url":"https://clinicaltrials.gov/study/NCT04756648","created_at":"2021-02-16T12:53:54.114Z","updated_at":"2024-07-02T16:35:42.852Z","phase":"Phase 1","brief_title":"Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma","source_id_and_acronym":"NCT04756648 - CT0180-CG1203","lead_sponsor":"Zhejiang University","biomarkers":" PD-L1 • GPC3","pipe":"","alterations":" ","tags":["PD-L1 • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CT0180"],"overall_status":"Recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 03/10/2021","start_date":" 03/10/2021","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-07-17"},{"id":"e4b393b3-b65e-452f-aeec-1ccd93781526","acronym":"","url":"https://clinicaltrials.gov/study/NCT05352542","created_at":"2022-04-29T12:54:54.174Z","updated_at":"2024-07-02T16:35:43.460Z","phase":"Phase 1","brief_title":"GPC3-targeting LCAR-H93T Cell in Treatment of Advanced Hepatocellular Carcinoma","source_id_and_acronym":"NCT05352542","lead_sponsor":"jianming xu","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LB2101"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 05/19/2022","start_date":" 05/19/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2023-07-11"},{"id":"f621ba59-cb59-4206-a05e-20a12949ff48","acronym":"","url":"https://clinicaltrials.gov/study/NCT04377932","created_at":"2021-01-19T19:44:24.215Z","updated_at":"2024-07-02T16:35:43.615Z","phase":"Phase 1","brief_title":"Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors","source_id_and_acronym":"NCT04377932","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AGAR T cells • GLYCAR T cells • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/08/2021","start_date":" 12/08/2021","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2040","study_completion_date":" 02/01/2040","last_update_posted":"2023-07-07"},{"id":"3495dd76-1b46-4800-9899-bf06b5891f99","acronym":"","url":"https://clinicaltrials.gov/study/NCT05926726","created_at":"2023-07-03T17:09:29.659Z","updated_at":"2024-07-02T16:35:44.207Z","phase":"","brief_title":"GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma","source_id_and_acronym":"NCT05926726","lead_sponsor":"RenJi Hospital","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-06-30"},{"id":"fb860809-ebea-4c05-af96-bfe14c08cdf3","acronym":"","url":"https://clinicaltrials.gov/study/NCT02932956","created_at":"2021-03-12T11:53:07.388Z","updated_at":"2024-07-02T16:35:46.433Z","phase":"Phase 1","brief_title":"Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)","source_id_and_acronym":"NCT02932956","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • GAP T cells • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 12/17/2018","start_date":" 12/17/2018","primary_txt":" Primary completion: 09/27/2021","primary_completion_date":" 09/27/2021","study_txt":" Completion: 02/01/2037","study_completion_date":" 02/01/2037","last_update_posted":"2023-06-06"},{"id":"76788d04-ecba-4ab1-ae56-720959e57ded","acronym":"ZZCART-003","url":"https://clinicaltrials.gov/study/NCT03198546","created_at":"2021-03-26T09:09:10.078Z","updated_at":"2024-07-02T16:35:54.565Z","phase":"Phase 1","brief_title":"GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression","source_id_and_acronym":"NCT03198546 - ZZCART-003","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 expression • GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 expression • GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TGFβ targeting CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2023-02-28"},{"id":"0e2c53e2-5daa-4613-9cf4-4a3a1038b338","acronym":"","url":"https://clinicaltrials.gov/study/NCT03198052","created_at":"2021-01-18T15:46:10.109Z","updated_at":"2024-07-02T16:35:55.664Z","phase":"Phase 1","brief_title":"GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers","source_id_and_acronym":"NCT03198052","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA","pipe":" | ","alterations":" MSLN expression • EGFR positive • GPC3 expression","tags":["EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • EGFR positive • GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-02-14"},{"id":"1d6660e2-1c5f-4568-b402-d32f87fd42b8","acronym":"CISLD-4","url":"https://clinicaltrials.gov/study/NCT03980288","created_at":"2021-01-19T18:10:57.427Z","updated_at":"2024-07-02T16:35:56.757Z","phase":"Phase 1","brief_title":"4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3","source_id_and_acronym":"NCT03980288 - CISLD-4","lead_sponsor":"Zhejiang University","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • CT0180"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 07/23/2019","start_date":" 07/23/2019","primary_txt":" Primary completion: 12/30/2020","primary_completion_date":" 12/30/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2023-01-31"},{"id":"38d28b1c-b832-4135-9431-71952b7272aa","acronym":"","url":"https://clinicaltrials.gov/study/NCT05620706","created_at":"2022-11-17T14:57:08.278Z","updated_at":"2024-07-02T16:36:00.046Z","phase":"","brief_title":"Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma","source_id_and_acronym":"NCT05620706","lead_sponsor":"Shenzhen University General Hospital","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 10/31/2025","primary_completion_date":" 10/31/2025","study_txt":" Completion: 10/31/2028","study_completion_date":" 10/31/2028","last_update_posted":"2022-11-22"},{"id":"a9305ff1-8168-48d4-a6d2-1d32391a5c57","acronym":"","url":"https://clinicaltrials.gov/study/NCT05344664","created_at":"2022-04-25T21:58:10.116Z","updated_at":"2024-07-02T16:36:11.522Z","phase":"Phase 1","brief_title":"Novel GPC3 CAR-T Cell Therapy for Hepatocellular Carcinoma","source_id_and_acronym":"NCT05344664","lead_sponsor":"Peking University","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3-CAR-T cells"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 04/14/2022","start_date":" 04/14/2022","primary_txt":" Primary completion: 10/14/2024","primary_completion_date":" 10/14/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2022-04-25"}]